{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:55:13Z","timestamp":1791262513442,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"DOI":"10.1007\/s00428-026-04740-7","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:31:14Z","timestamp":1791261074000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Alternative lengthening of telomeres in small well-differentiated pancreatic neuroendocrine tumors: independent validation and cross-platform concordance"],"prefix":"10.1007","author":[{"given":"Ameya","family":"Patil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raima","family":"Memon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hallberra","family":"Gudmundsdottir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorvardur R.","family":"Halfdanarson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Greipp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Vrana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Rech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Al Diffalha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle D.","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela S.","family":"Allende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8686-4867","authenticated-orcid":false,"given":"Rondell P.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"issue":"1","key":"4740_CR1","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1097\/PAP.0000000000000369","volume":"30","author":"Z Alipour","year":"2023","unstructured":"Alipour Z, Sweeney JR, Zhang Q, Yang Z (2023) Neuroendocrine neoplasms of the pancreas: diagnostic challenges and practical approach. Adv Anat Pathol 30(1):58\u201368. https:\/\/doi.org\/10.1097\/PAP.0000000000000369","journal-title":"Adv Anat Pathol"},{"issue":"7","key":"4740_CR2","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1093\/oncolo\/oyac049","volume":"27","author":"MB Sonbol","year":"2022","unstructured":"Sonbol MB, Mazza GL, Mi L et al (2022) Survival and incidence patterns of pancreatic neuroendocrine tumors over the last 2 decades: a SEER database analysis. Oncologist 27(7):573\u2013578. https:\/\/doi.org\/10.1093\/oncolo\/oyac049","journal-title":"Oncologist"},{"issue":"6","key":"4740_CR3","doi-asserted-by":"publisher","first-page":"e2515798","DOI":"10.1001\/jamanetworkopen.2025.15798","volume":"8","author":"A Dasari","year":"2025","unstructured":"Dasari A, Wallace K, Halperin DM et al (2025) Epidemiology of neuroendocrine neoplasms in the US. JAMA Netw Open 8(6):e2515798. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.15798","journal-title":"JAMA Netw Open"},{"issue":"3","key":"4740_CR4","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1097\/MPA.0000000000001256","volume":"48","author":"JF Hechtman","year":"2019","unstructured":"Hechtman JF, Klimstra DS, Nanjangud G, Frosina D, Shia J, Jungbluth AA (2019) Performance of DAXX immunohistochemistry as a screen for DAXX mutations in pancreatic neuroendocrine tumors. Pancreas 48(3):396\u2013399. https:\/\/doi.org\/10.1097\/MPA.0000000000001256","journal-title":"Pancreas"},{"issue":"2","key":"4740_CR5","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1158\/1078-0432.CCR-16-1113","volume":"23","author":"AD Singhi","year":"2017","unstructured":"Singhi AD, Liu TC, Roncaioli JL et al (2017) Alternative lengthening of telomeres and loss of DAXX\/ATRX expression predicts metastatic disease and poor survival in patients with pancreatic neuroendocrine tumors. Clin Cancer Res 23(2):600\u2013609. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1113","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4740_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/MPA.0000000000001454","volume":"49","author":"JR Howe","year":"2020","unstructured":"Howe JR, Merchant NB, Conrad C et al (2020) The North American Neuroendocrine Tumor Society Consensus Paper on the surgical management of pancreatic neuroendocrine tumors. Pancreas 49(1):1\u201333. https:\/\/doi.org\/10.1097\/MPA.0000000000001454","journal-title":"Pancreas"},{"issue":"12","key":"4740_CR7","doi-asserted-by":"publisher","first-page":"e13343","DOI":"10.1111\/jne.13343","volume":"35","author":"B Kos-Kudla","year":"2023","unstructured":"Kos-Kudla B, Castano JP, Denecke T et al (2023) European Neuroendocrine Tumour Society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours. J Neuroendocrinol Dec 35(12):e13343. https:\/\/doi.org\/10.1111\/jne.13343","journal-title":"J Neuroendocrinol Dec"},{"key":"4740_CR8","doi-asserted-by":"publisher","first-page":"S1580","DOI":"10.1016\/j.annonc.2025.09.047","volume":"36","author":"S Partelli","year":"2025","unstructured":"Partelli S, Andreasi V, Zerbi A et al (2025) LBA36 Management of asymptomatic sporadic nonfunctioning pancreatic neuroendocrine neoplasms \u22642 cm: a prospective international observational multicentric cohort study (ASPEN study). Ann Oncol 36:S1580. https:\/\/doi.org\/10.1016\/j.annonc.2025.09.047","journal-title":"Ann Oncol"},{"key":"4740_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-55156-0","author":"M Cives","year":"2019","unstructured":"Cives M, Partelli S, Palmirotta R et al (2019) DAXX mutations as potential genomic markers of malignant evolution in small nonfunctioning pancreatic neuroendocrine tumors. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-019-55156-0","journal-title":"Sci Rep"},{"issue":"2","key":"4740_CR10","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1159\/000524920","volume":"90","author":"DM Gisder","year":"2023","unstructured":"Gisder DM, Overheu O, Keller J et al (2023) DAXX, ATRX, and MSI in PanNET and Their Metastases: Correlation with Histopathological Data and Prognosis. Pathobiology 90(2):71\u201380. https:\/\/doi.org\/10.1159\/000524920","journal-title":"Pathobiology"},{"key":"4740_CR11","unstructured":"Board WHOCTE (2026) Digestive System Tumours. 6th, beta version ed. WHO Classification of Tumours series, 6th ed. International Agency for Research on Cancer"},{"key":"4740_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s13578-021-00660-y","author":"C Wang","year":"2021","unstructured":"Wang C, Songyang Z, Huang Y (2021) TRIM28 inhibits alternative lengthening of telomere phenotypes by protecting SETDB1 from degradation. Cell Biosci. https:\/\/doi.org\/10.1186\/s13578-021-00660-y","journal-title":"Cell Biosci"},{"key":"4740_CR13","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-24-0305","author":"AVD Verschuur","year":"2025","unstructured":"Verschuur AVD, Chen L, Nieveen van Dijkum EJ et al (2025) Management of patients with small pancreatic neuroendocrine tumors from a biomarker and surgical perspective. Endocr Relat Cancer. https:\/\/doi.org\/10.1530\/ERC-24-0305","journal-title":"Endocr Relat Cancer"},{"key":"4740_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.humpath.2023.01.004","volume":"132","author":"CM Heaphy","year":"2023","unstructured":"Heaphy CM, Singhi AD (2023) Reprint of: the diagnostic and prognostic utility of incorporating DAXX, ATRX, and alternative lengthening of telomeres (ALT) to the evaluation of pancreatic neuroendocrine tumors (PanNETs). Hum Pathol 132:1\u201311. https:\/\/doi.org\/10.1016\/j.humpath.2023.01.004","journal-title":"Hum Pathol"},{"issue":"1","key":"4740_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-025-09889-6","volume":"36","author":"S Avanthay","year":"2025","unstructured":"Avanthay S, Di Domenico A, Kirchner P et al (2025) Molecular subtypes of pancreatic neuroendocrine tumors mutated in MEN1\/DAXX\/ATRX explain biological variability. Endocr Pathol 36(1):44. https:\/\/doi.org\/10.1007\/s12022-025-09889-6","journal-title":"Endocr Pathol"},{"key":"4740_CR16","doi-asserted-by":"publisher","unstructured":"MacKenzie D Jr., Watters AK, To JT et al (2021) ALT positivity in human cancers: prevalence and clinical insights. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13102384","DOI":"10.3390\/cancers13102384"},{"issue":"7","key":"4740_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1002772","volume":"8","author":"CA Lovejoy","year":"2012","unstructured":"Lovejoy CA, Li W, Reisenweber S et al (2012) Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway. PLoS Genet 8(7):e1002772. https:\/\/doi.org\/10.1371\/journal.pgen.1002772","journal-title":"PLoS Genet"},{"key":"4740_CR18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.humpath.2022.07.015","volume":"129","author":"CM Heaphy","year":"2022","unstructured":"Heaphy CM, Singhi AD (2022) The diagnostic and prognostic utility of incorporating DAXX, ATRX, and alternative lengthening of telomeres to the evaluation of pancreatic neuroendocrine tumors. Hum Pathol 129:11\u201320. https:\/\/doi.org\/10.1016\/j.humpath.2022.07.015","journal-title":"Hum Pathol"},{"issue":"3","key":"4740_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2024.100651","volume":"38","author":"CM Heaphy","year":"2025","unstructured":"Heaphy CM, Patel S, Smith K et al (2025) Detection of alternative lengthening of telomeres via chromogenic in situ hybridization for the prognostication of PanNETs and other neoplasms. Mod Pathol 38(3):100651. https:\/\/doi.org\/10.1016\/j.modpat.2024.100651","journal-title":"Mod Pathol"},{"issue":"8","key":"4740_CR20","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1093\/bjs\/znab088","volume":"108","author":"CM Heidsma","year":"2021","unstructured":"Heidsma CM, Engelsman AF, van Dieren S et al (2021) Watchful waiting for small non-functional pancreatic neuroendocrine tumours: nationwide prospective cohort study (PANDORA). Br J Surg 108(8):888\u2013891. https:\/\/doi.org\/10.1093\/bjs\/znab088","journal-title":"Br J Surg"},{"issue":"5","key":"4740_CR21","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1136\/gutjnl-2020-322595","volume":"71","author":"WM Hackeng","year":"2022","unstructured":"Hackeng WM, Brosens LAA, Kim JY et al (2022) Non-functional pancreatic neuroendocrine tumours: ATRX\/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX\/PDX1 expression and tumour size. Gut 71(5):961\u2013973. https:\/\/doi.org\/10.1136\/gutjnl-2020-322595","journal-title":"Gut"},{"issue":"2","key":"4740_CR22","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/his.15025","volume":"84","author":"C Mestre-Alagarda","year":"2024","unstructured":"Mestre-Alagarda C, Srirajaskanthan R, Zen Y, Giwa M, Howard M, Ooft ML (2024) Genetic and epigenetic prognosticators of neuroendocrine tumours of the GI tract, liver, biliary tract and pancreas: a systematic review and meta-analysis. Histopathology 84(2):255\u2013265. https:\/\/doi.org\/10.1111\/his.15025","journal-title":"Histopathology"},{"key":"4740_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.691557","volume":"12","author":"F Wang","year":"2021","unstructured":"Wang F, Xu X, Ye Z, Qin Y, Yu X, Ji S (2021) Prognostic significance of altered ATRX\/DAXX gene in pancreatic neuroendocrine tumors: a meta-analysis. Front Endocrinol (Lausanne) 12:691557. https:\/\/doi.org\/10.3389\/fendo.2021.691557","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6041","key":"4740_CR24","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1126\/science.1207313","volume":"333","author":"CM Heaphy","year":"2011","unstructured":"Heaphy CM, de Wilde RF, Jiao Y et al (2011) Altered telomeres in tumors with ATRX and DAXX mutations. Science 333(6041):425. https:\/\/doi.org\/10.1126\/science.1207313","journal-title":"Science"},{"issue":"3","key":"4740_CR25","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1097\/SLA.0000000000003022","volume":"271","author":"A Pea","year":"2020","unstructured":"Pea A, Yu J, Marchionni L et al (2020) Genetic analysis of small well-differentiated pancreatic neuroendocrine tumors identifies subgroups with differing risks of liver metastases. Ann Surg 271(3):566\u2013573. https:\/\/doi.org\/10.1097\/SLA.0000000000003022","journal-title":"Ann Surg"},{"issue":"6","key":"4740_CR26","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1158\/1078-0432.CCR-16-1147","volume":"23","author":"JY Kim","year":"2017","unstructured":"Kim JY, Brosnan-Cashman JA, An S et al (2017) Alternative lengthening of telomeres in primary pancreatic neuroendocrine tumors is associated with aggressive clinical behavior and poor survival. Clin Cancer Res 23(6):1598\u20131606. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1147","journal-title":"Clin Cancer Res"},{"issue":"2","key":"4740_CR27","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s12022-020-09611-8","volume":"31","author":"WM Hackeng","year":"2020","unstructured":"Hackeng WM, Schelhaas W, Morsink FHM et al (2020) Alternative lengthening of telomeres and differential expression of endocrine transcription factors distinguish metastatic and non-metastatic insulinomas. Endocr Pathol 31(2):108\u2013118. https:\/\/doi.org\/10.1007\/s12022-020-09611-8","journal-title":"Endocr Pathol"},{"issue":"4","key":"4740_CR28","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1007\/s12022-024-09826-z","volume":"35","author":"P Mattiolo","year":"2024","unstructured":"Mattiolo P, Bevere M, Mafficini A et al (2024) Glucagon-producing pancreatic neuroendocrine tumors (glucagonomas) are enriched in aggressive neoplasms with ARX and PDX1 co-expression, DAXX\/ATRX mutations, and ALT (alternative lengthening of telomeres). Endocr Pathol 35(4):354\u2013361. https:\/\/doi.org\/10.1007\/s12022-024-09826-z","journal-title":"Endocr Pathol"},{"issue":"7","key":"4740_CR29","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1038\/modpathol.2012.53","volume":"25","author":"CM Wilde RFd, Heaphy","year":"2012","unstructured":"Wilde RFd, Heaphy CM, Maitra A et al (2012) Loss of ATRX or DAXX Expression and Concomitant Acquisition of the Alternative Lengthening of Telomeres Phenotype Are Late Events in a Small Subset of MEN-1 Syndrome Pancreatic Neuroendocrine Tumors. Mod Pathol 25(7):1033\u20131039. https:\/\/doi.org\/10.1038\/modpathol.2012.53","journal-title":"Mod Pathol"},{"issue":"8","key":"4740_CR30","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/modpathol.2015.67","volume":"28","author":"JC Lee","year":"2015","unstructured":"Lee JC, Jeng YM, Liau JY, Tsai J-H, Hsu H-H, Yang C-Y (2015) Alternative Lengthening of Telomeres and Loss of ATRX Are Frequent Events in Pleomorphic and Dedifferentiated Liposarcomas. Mod Pathol 28(8):1064\u20131073. https:\/\/doi.org\/10.1038\/modpathol.2015.67","journal-title":"Mod Pathol"},{"issue":"7","key":"4740_CR31","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1017\/S0022215109992854","volume":"124","author":"W Chen","year":"2010","unstructured":"Chen W, Chen SM, Yu Y, Xiao BK, Huang ZW, Tao ZZ (2010) Telomerase inhibition alters telomere maintenance mechanisms in laryngeal squamous carcinoma cells. J Laryngol Otol 124(7):778\u201383. https:\/\/doi.org\/10.1017\/S0022215109992854","journal-title":"J Laryngol Otol"},{"issue":"4","key":"4740_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/genes14040790","volume":"14","author":"SFC Soper","year":"2023","unstructured":"Soper SFC, Meltzer PS (2023) ATRX\/DAXX: guarding the genome against the hazards of ALT. Genes (Basel) 14(4):790. https:\/\/doi.org\/10.3390\/genes14040790","journal-title":"Genes (Basel)"},{"issue":"1","key":"4740_CR33","doi-asserted-by":"publisher","first-page":"219","DOI":"10.21037\/gs-20-582","volume":"10","author":"X Liu","year":"2021","unstructured":"Liu X, Chin W, Pan C et al (2021) Risk of malignancy and prognosis of sporadic resected small (=2\u00a0cm) nonfunctional pancreatic neuroendocrine tumors<\/at. Gland Surg Jan 10(1):219\u2013232. https:\/\/doi.org\/10.21037\/gs-20-582","journal-title":"Gland Surg Jan"},{"issue":"4","key":"4740_CR34","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1245\/s10434-025-18887-1","volume":"33","author":"V Podrascanin","year":"2026","unstructured":"Podrascanin V, Ammann M, Gudmundsdottir H et al (2026) The paradox of grade 2 pancreatic neuroendocrine tumors: G2a\/G2b subdivision in patients with and without liver metastases: a retrospective single-center analysis. Ann Surg Oncol 33(4):3425\u20133434. https:\/\/doi.org\/10.1245\/s10434-025-18887-1","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"4740_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-04356-y","volume":"15","author":"Y Kageyama","year":"2025","unstructured":"Kageyama Y, Ashida R, Ohike N et al (2025) Stratification of G2 pancreatic neuroendocrine tumors using a ten percent Ki-67 index cut-off based on clinicopathological and molecular analyses. Sci Rep 15(1):18919. https:\/\/doi.org\/10.1038\/s41598-025-04356-y","journal-title":"Sci Rep"},{"issue":"10","key":"4740_CR36","doi-asserted-by":"publisher","first-page":"7001","DOI":"10.1245\/s10434-024-15632-y","volume":"31","author":"OC Eren","year":"2024","unstructured":"Eren OC, Bagci P, Balci S et al (2024) Subgrading of G2 Pancreatic Neuroendocrine Tumors as 2A (Ki67 3% to <\u200910%) Versus 2B (10% to = 20%) Identifies Behaviorally Distinct Subsets in Keeping with the Evolving Management Protocols<\/at. Ann Surg Oncol Oct 31(10):7001\u20137011. https:\/\/doi.org\/10.1245\/s10434-024-15632-y","journal-title":"Ann Surg Oncol Oct"},{"key":"4740_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.657698","volume":"12","author":"J Calissendorff","year":"2021","unstructured":"Calissendorff J, Bjellerup-Calissendorff F, Branstrom R, Juhlin CC, Falhammar H (2021) Characteristics, treatment, outcomes, and survival in neuroendocrine G1 and G2 pancreatic tumors: experiences from a single tertiary referral center. Front Endocrinol (Lausanne) 12:657698. https:\/\/doi.org\/10.3389\/fendo.2021.657698","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"4740_CR38","doi-asserted-by":"publisher","DOI":"10.1111\/jne.70003","volume":"37","author":"H Gudmundsdottir","year":"2025","unstructured":"Gudmundsdottir H, Graham RP, Greipp PT et al (2025) Alternative lengthening of telomeres and Ki-67 proliferation index provide complementary information on recurrence risk after resection of pancreatic neuroendocrine tumors. J Neuroendocrinol 37(4):e70003. https:\/\/doi.org\/10.1111\/jne.70003","journal-title":"J Neuroendocrinol"},{"issue":"3","key":"4740_CR39","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/ases.12107","volume":"7","author":"M Usui","year":"2014","unstructured":"Usui M, Kuriyama N, Uchida K et al (2014) Laparoscopy assisted middle-segment-preserving pancreatectomy for multiple pancreatic neuroendocrine tumors: report of a case. Asian J Endosc Surg 7(3):271\u20134. https:\/\/doi.org\/10.1111\/ases.12107","journal-title":"Asian J Endosc Surg"},{"key":"4740_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.928341","author":"Z Yang","year":"2022","unstructured":"Yang Z, Zhang D, Shi G (2022) Reappraisal of a 2-Cm cutoff size for the management of nonfunctional pancreatic neuroendocrine tumors: a population-based study. Front Endocrinol. https:\/\/doi.org\/10.3389\/fendo.2022.928341","journal-title":"Front Endocrinol"},{"issue":"7","key":"4740_CR41","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1002\/cncy.21857","volume":"125","author":"CJ VandenBussche","year":"2017","unstructured":"VandenBussche CJ, Allison DB, Graham MK et al (2017) Alternative lengthening of telomeres and ATRX\/DAXX loss can be reliably detected in FNAs of pancreatic neuroendocrine tumors. Cancer Cytopathol 125(7):544\u2013551. https:\/\/doi.org\/10.1002\/cncy.21857","journal-title":"Cancer Cytopathol"},{"issue":"7","key":"4740_CR42","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1097\/PAS.0000000000001447","volume":"44","author":"E Baranov","year":"2020","unstructured":"Baranov E, McBride MJ, Bellizzi AM et al (2020) A Novel SS18-SSX Fusion-specific Antibody for the Diagnosis of Synovial Sarcoma. Am J Surg Pathol 44(7):922\u2013933. https:\/\/doi.org\/10.1097\/PAS.0000000000001447","journal-title":"Am J Surg Pathol"},{"key":"4740_CR43","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1038\/modpathol.3800432","volume":"18","author":"Y Gong","year":"2005","unstructured":"Gong Y, Gilcrease M, Sneige N (2005) Reliability of chromogenic in situ hybridization for detecting HER-2 gene status in breast cancer: comparison with fluorescence in situ hybridization and assessment of interobserver reproducibility. Mod Pathol 18:1015\u20131021. https:\/\/doi.org\/10.1038\/modpathol.3800432","journal-title":"Mod Pathol"},{"issue":"5","key":"4740_CR44","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/S0002-9440(10)64785-2","volume":"157","author":"M Tanner","year":"2000","unstructured":"Tanner M, Gancberg D, Di Leo A et al (2000) Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2\/neu oncogene amplification in archival breast cancer samples. Am J Pathol 157(5):1467\u20131472","journal-title":"Am J Pathol"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-026-04740-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-026-04740-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-026-04740-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:31:30Z","timestamp":1791261090000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-026-04740-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":44,"alternative-id":["4740"],"URL":"https:\/\/doi.org\/10.1007\/s00428-026-04740-7","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"assertion":[{"value":"26 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Mayo Clinic Institutional Review Board (IRB).","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No authors in this study declare any competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Allende declared advisory board member activities with Gilead, royalties from Elsevier and honoraria from speaker engagements with Educational Symposia. The contributing authors and their corresponding institutions declare that they have no personal or financial conflicts of interest. All co-authors have had the opportunity to review the contents of the manuscript. We declare that the content of this research is original work and not under review by any other publisher.","order":3,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}